<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04856436</url>
  </required_header>
  <id_info>
    <org_study_id>SKKU-2021-PREG-BZ</org_study_id>
    <nct_id>NCT04856436</nct_id>
  </id_info>
  <brief_title>Maternal and Neonatal Outcomes Following Exposure to Benzodiazepines During Pregnancy</brief_title>
  <official_title>Maternal and Neonatal Outcomes Following Benzodiazepine Use During Pregnancy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sungkyunkwan University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Research Foundation of Korea</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Sungkyunkwan University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a nationwide cohort study to assess maternal and neonatal outcomes following exposure&#xD;
      to benzodiazepines during pregnancy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Benzodiazepines are widely used in pregnant women; however, their safety on congenital&#xD;
      malformations in a real-world setting is still uncertain. We aimed to assess the association&#xD;
      between benzodiazepine use in early pregnancy and the risk of congenital malformations. We&#xD;
      will conduct a retrospective nationwide cohort study using the Health Insurance Review and&#xD;
      Assessment (HIRA) database of South Korea, which covers the entire South Korean population.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 1, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Risk of congenital malformations</measure>
    <time_frame>from the birth date until up to 8 years, death, or study end date (Dec 31, 2019)</time_frame>
    <description>Overall congenital malformations and organ-specific congenital malformations in infants, which are confirmed by diagnostic records in the HIRA database. All infants were followed up for at least 1 year.</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">3000000</enrollment>
  <condition>Pregnancy Related</condition>
  <condition>Benzodiazepines Causing Adverse Effects in Therapeutic Use</condition>
  <condition>Congenital Anomaly</condition>
  <arm_group>
    <arm_group_label>Pregnant women with exposure to benzodiazepines</arm_group_label>
    <description>Women who gave birth during 2011-2018, were aged 20-45 years and were filled at least one benzodiazepine prescription during the first trimester (first 90 days of pregnancy).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pregnant women without exposure to benzodiazepines</arm_group_label>
    <description>Women who gave birth during 2011-2018, were aged 20-45 years and did not fill a benzodiazepine prescription during the 3 months before the pregnancy onset through the end of the first trimester</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Benzodiazepine</intervention_name>
    <description>Exposure to benzodiazepine during early pregnancy</description>
    <arm_group_label>Pregnant women with exposure to benzodiazepines</arm_group_label>
    <arm_group_label>Pregnant women without exposure to benzodiazepines</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Pregnant women who gave birth in South Korea between 2011 and 2018&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Pregnancies with live birth, 2011-2018&#xD;
&#xD;
          -  Pregnancies linked to liveborn infants&#xD;
&#xD;
          -  Pregnancies aged 20-45 years at delivery&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnancies with a chromosomal abnormality&#xD;
&#xD;
          -  Pregnancies with exposure to known teratogenic drugs (e.g. antineoplastic agent,&#xD;
             warfarin, lithium, isotretinoin, misoprostol, thalidomide) during the first trimester&#xD;
&#xD;
          -  Pregnancies with no benzodiazepine prescription during the first trimester, but with&#xD;
             at least one benzodiazepine prescription during the 3 months before the pregnancy&#xD;
             onset&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ju-Young Shin, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sungkyunkwan University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yunha Noh, PharmD</last_name>
    <phone>+82-31-299-4377</phone>
    <email>noh.yh@skku.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Sungkyunkwan University</name>
      <address>
        <city>Suwon</city>
        <state>Gyeonggi-do</state>
        <zip>16419</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ju-Young Shin, PhD</last_name>
      <phone>+82-31-299-4377</phone>
      <email>shin.jy@skku.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <reference>
    <citation>Bellantuono C, Tofani S, Di Sciascio G, Santone G. Benzodiazepine exposure in pregnancy and risk of major malformations: a critical overview. Gen Hosp Psychiatry. 2013 Jan-Feb;35(1):3-8. doi: 10.1016/j.genhosppsych.2012.09.003. Epub 2012 Oct 6. Review.</citation>
    <PMID>23044244</PMID>
  </reference>
  <reference>
    <citation>Grigoriadis S, Graves L, Peer M, Mamisashvili L, Dennis CL, Vigod SN, Steiner M, Brown C, Cheung A, Dawson H, Rector N, Guenette M, Richter M. Benzodiazepine Use During Pregnancy Alone or in Combination With an Antidepressant and Congenital Malformations: Systematic Review and Meta-Analysis. J Clin Psychiatry. 2019 Jul 9;80(4). pii: 18r12412. doi: 10.4088/JCP.18r12412.</citation>
    <PMID>31294935</PMID>
  </reference>
  <reference>
    <citation>Bais B, Molenaar NM, Bijma HH, Hoogendijk WJG, Mulder CL, Luik AI, Lambregtse-van den Berg MP, Kamperman AM. Prevalence of benzodiazepines and benzodiazepine-related drugs exposure before, during and after pregnancy: A systematic review and meta-analysis. J Affect Disord. 2020 May 15;269:18-27. doi: 10.1016/j.jad.2020.03.014. Epub 2020 Mar 5. Review.</citation>
    <PMID>32217339</PMID>
  </reference>
  <reference>
    <citation>Iqbal MM, Sobhan T, Ryals T. Effects of commonly used benzodiazepines on the fetus, the neonate, and the nursing infant. Psychiatr Serv. 2002 Jan;53(1):39-49. Review.</citation>
    <PMID>11773648</PMID>
  </reference>
  <reference>
    <citation>Shyken JM, Babbar S, Babbar S, Forinash A. Benzodiazepines in Pregnancy. Clin Obstet Gynecol. 2019 Mar;62(1):156-167. doi: 10.1097/GRF.0000000000000417. Review.</citation>
    <PMID>30628916</PMID>
  </reference>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>April 19, 2021</study_first_submitted>
  <study_first_submitted_qc>April 19, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 23, 2021</study_first_posted>
  <last_update_submitted>April 19, 2021</last_update_submitted>
  <last_update_submitted_qc>April 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sungkyunkwan University</investigator_affiliation>
    <investigator_full_name>Ju-Young Shin</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Congenital Abnormalities</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

